Article Text

Download PDFPDF

733 Our experience in ovarian cancer 2006–2015 . Standards of quality in surgical management
  1. O Arencibia Sanchez,
  2. AF Rave Ramirez,
  3. D González García-Cano,
  4. M Laseca Modrego and
  5. A Martín Martínez
  1. Complejo Hospitalario Universitario Insular Materno Infantil de Gran Canaria , Gynecologic Oncology, las palmas de gran canaria, Spain


Introduction/Background*It is important to know the survival data of patients with ovarian cancer treated in our unit,the variables associated with the prognosis and the degree of compliance with the standards in the surgical management of ovarian cancer

Methodology Retrospective study of patients with ovarian cancer diagnosed and treated in CHUIMI in the period between 2006-2015.We studied epidemiological variables,stage at diagnosis,type of treatment,histopathological study,follow up and current status of patients.

Result(s)*The total number of patients diagnosed with ovarian cancer in the study period was 331,with a mean age of 57.84 years (range 26–85 years).69.8% were in advanced stages at the time of diagnosis (Stage I 23.9% (79),Stage II 6.3% (21),Stage III 54.1% (179) and Stage IV 15.7% (52).

Regarding the histological type,serous was the most frequent representing 49.8% of the sample, followed by endometrioid with 16.3% and clear cells with 10.9%.We found that endometrioid,clear cells and mucinous types were more frequent in the grupo diagnosed with eraly stages versus the serous type that were more associated with the advanced disease.

Overall survival (OS) at 5 years is 40.8% for the complete series. 83.3% for stages I, 72.2% for stages II, 29.1% for stages III and there are no patients in stage IV who lived after 5 years. In stages III, the most frequent therapeutic approach is initial surgery in 41.1%, followed by neoadjuvant chemotherapy in 30.3%. Stage III patients receiving surgery + adjuvant chemotherapy showed an OS of 47% at 5 years (median survival 44 months) meanwhile those who received neoadyuvant chemotherapy and get the surgery in second place showed an OS of 27.1% (median survival 35 months).

When we studied the effect of tumor residue after surgery in stage III patients, the OS when the surgery was complete was 52,9% at five years, 15% if there were residual tumour, regardless of the size. Initial surgery was performed in 58% of all stages III-IV (objective> 50%). Complete citoreduction was achieved in 51% of all stages III-IV (minimum objective> 50%, optimal> 65%)

Conclusion*Our epidemiological and survival data coincide with what has been published in the literature.Having surgeons with experience in the management of peritoneal carcinomatosis will allow to increase the rate of complete citoreductions

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.